



**U. S. Department of Justice**  
**Drug Enforcement Administration**  
8701 Morrissette Drive  
Springfield, Virginia 22152

---

*www.dea.gov*

Eric A. Dubelier, Esq.  
Reed Smith LLP  
1301 K Street, N.W.  
Suite 1100 - East Tower  
Washington, D.C. 20005-3373

**MAY 03 2012**

Dear Mr. Dubelier:

This letter responds to your October 25, 2010, correspondence to Mr. Harry Matz as well as ongoing communications with the United States Attorney's Office for the Northern District of Ohio regarding your client's, Omnicare, Inc. (Omnicare), proposed "reminder letters" for prescribing practitioners. (See enclosed attachments A-1, A-2, B-1, B-2, C-1, and C-2).

The Drug Enforcement Administration (DEA) recognizes the importance of providing medications to patients residing in long-term care facilities in a timely and efficient manner. DEA also recognizes that these patients are often frail with multiple illnesses. It is therefore most important that any attempt to streamline this process does not diminish the doctor-patient relationship or otherwise weaken the quality of care for the frail and infirm. It is also important to ensure that any use of such letters is done so in conformity with all local, state, and federal laws and regulations.

One of the most important principles underlying the Controlled Substances Act (CSA) and its implementing regulations is that every prescription for a controlled substance must be predicated on a determination by an individual practitioner that the dispensing of the controlled substance is for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. 21 C.F.R. §1306.04(a) and *United States v Moore*, 423 U.S. 122 (1975). Therefore, the use of any "reminder letter" such as those developed by Omnicare (see attachments A-1, A-2, B-1, B-2, C-1, and C-2) must comply with this requirement.

Each of the attached letters contains a pre-printed form for use by prescribing practitioners. Each of the attachments, however, is designed for different circumstances. Attachments A-1 and A-2 notify prescribers that a previously authorized controlled substance prescription is about to expire and asks the practitioner whether he or she wishes to issue a new prescription for the patient. The top of these two letters each provides information such as the patient's name, date of birth, address, and previously prescribed medication. These letters instruct the prescriber to prepare and fax a valid prescription to the pharmacy if the prescriber wishes to continue drug therapy for the patient. Attachments B-1 and B-2 are reminder letters for compliance with 21 CFR §1306.11(d)(4) after an emergency oral prescription has been issued by a practitioner to a pharmacy.

Attachments C-1 and C-2 are similar to B-1 and B-2; however, C-1 and C-2 contain pre-populated information within the "prescription" portion of the reminder letter. Unlike the letters identified as A-1, A-2, B-1 and B-2, DEA rejects the use of the letters identified as C-1 or C-2 by Omnicare for several reasons. As stated above, a practitioner may authorize a controlled substance prescription only after the prescribing practitioner determines that a prescription for a controlled substance is for a legitimate medical purpose and for a specific patient. Accordingly, a pharmacy may not initiate a reminder letter to a prescribing practitioner


that provides a partially or fully pre-populated form for the prescribing practitioner because the practitioner has not yet made the determination, in the usual course of professional practice, that there is a legitimate medical purpose for the prescription. In addition, the pharmacy may not be characterized as the prescribing practitioner's agent for purposes of preparing the prescription because the regulations require the practitioner to instruct his or her authorized agent as to the required elements of a valid prescription, not *vice versa*.

While the core responsibilities pertaining to prescribing controlled substances may not be delegated to anyone other than the prescribing practitioner, an individual practitioner may authorize an agent to perform a limited role in preparing a prescription for the practitioner's signature. 21 C.F.R. § 1306.05(f). An authorized agent may prepare a controlled substance prescription only based upon the instructions of the prescribing practitioner as to the required elements of a valid prescription. 21 C.F.R. §§ 1306.04(a), 1306.05(a), (f). Thus, the practitioner must *first* determine that a prescription for a controlled substance is for a legitimate medical purpose; then, the practitioner may authorize an agent to prepare the prescription and must instruct the agent as to the required elements of the prescription. The CSA defines an "agent" as "an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser." 21 U.S.C. § 802(3). Establishment of an agency relationship, consistent with the CSA, is guided by general precepts of the common law of agency.

Finally, to safeguard the integrity of the prescription process, DEA regulations establish a check and balance by imposing independent responsibilities on DEA registrants. DEA regulations specify that pharmacists have a corresponding responsibility with practitioners for the proper prescribing and dispensing of controlled substances and must ensure that prescriptions for controlled substances conform in all essential respects to the law and regulations. 21 C.F.R. §§ 1306.04(a) and 1306.05(f).

I hope this clarifies a pharmacy's responsibilities with regard to initiating "reminder letters" and pre-populating authorization forms for prescribers. Note that the comments herein only speak to the matter of pre-populating authorization forms for prescribers. Should you have any questions or require further clarification, please contact Section Chief John Partridge, Liaison Section, at (202) 307-7874.

Sincerely,



Joseph T. Rannazzisi  
Deputy Assistant Administrator  
Office of Diversion Control

Attachments: as stated

11/9/2011

A-1

DEA#  
PH#  
FAX#

**REQUEST FOR CIII-V CONTINUANCE OF THERAPY PRESCRIPTION**

**DEAR PRACTITIONER**

The current prescription for your patient has no refills remaining or is about to expire. If you want to continue therapy for your patient indicated below, please prepare and fax a valid signed written prescription to the pharmacy, or authorize a verbal prescription directly to the pharmacist. The prescription must contain all required elements of a controlled substance prescription as per 21 CFR 1306.05.

Pursuant to 21 CFR 1306.04(a), a prescription for a controlled substance to be effective must be issued for a legitimate medical purpose by a practitioner in the usual course of professional practice.

PATIENT:  
ADDRESS:

PAT ID:  
DOB:

MEDICATION: LORAZEPAM 0.5MG TABLET

DIRECTIONS: TAKE 1 TABLET ORALLY EVERY 6 HOURS AS NEEDED FOR ANXIETY

\*\*\* Valid controlled substance prescriptions must contain all of the required elements of a prescription listed below, along with your signature. Controlled substance prescriptions cannot be dispensed if any information listed below is incomplete. \*\*\*

Date: \_\_\_\_\_

Patient Full Name: \_\_\_\_\_

Patient Full Address: \_\_\_\_\_

Medication Name/Strength: \_\_\_\_\_

Dosage Form: \_\_\_\_\_

Quantity Prescribed: \_\_\_\_\_ (numeric)

\_\_\_\_\_ (alpha)

Directions for use: \_\_\_\_\_

Number of Refills: \_\_\_\_\_

Practitioner Name: \_\_\_\_\_

Practitioner Full Address: \_\_\_\_\_

Practitioner DEA Number: \_\_\_\_\_

Practitioner Signature: \_\_\_\_\_

This information is intended only for the person or entity to which it is address and may contain confidential and/or privileged material, the disclosure of which is governed by applicable law. Any review, retransmission, dissemination or other use of, or taking any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and destroy the materials contained in this message.

11/9/2011

A-2

DEA#  
PH#  
FAX#

**REQUEST FOR CII CONTINUANCE OF THERAPY PRESCRIPTION**

DEAR PRACTITIONER

The current prescription for your patient is about to expire. If you want to continue therapy for your LTCF patient indicated below, please prepare and fax a valid signed written prescription to the pharmacy. The prescription must contain all required elements of a controlled substance prescription as per 21 CFR 1306.05.

Pursuant to 21 CFR 1306.04(a), a prescription for a controlled substance to be effective must be issued for a legitimate medical purpose by a practitioner in the usual course of professional practice.

LTCF PATIENT:  
ADDRESS:

PAT ID:  
DOB:

MEDICATION: MS CONTIN 30MG TABLET SA

DIRECTIONS: TAKE 1 TABLET ORALLY EVERY 12 HOURS FOR PAIN

\*\*\* Valid controlled substance prescriptions must contain all of the required elements of a prescription listed below, along with your signature. Controlled substance prescriptions cannot be dispensed if any information listed below is incomplete. \*\*\*

Date: \_\_\_\_\_

Patient Full Name: \_\_\_\_\_

Patient Full Address: \_\_\_\_\_  
\_\_\_\_\_

Medication Name/Strength: \_\_\_\_\_

Dosage Form: \_\_\_\_\_

Quantity Prescribed: \_\_\_\_\_ (numeric)

Directions for use: \_\_\_\_\_ (alpha)

Practitioner Name: \_\_\_\_\_

Practitioner Full Address: \_\_\_\_\_  
\_\_\_\_\_

Practitioner DEA Number: \_\_\_\_\_

Practitioner Signature: \_\_\_\_\_

This information is intended only for the person or entity to which it is address and may contain confidential and/or privileged material, the disclosure of which is governed by applicable law. Any review, retransmission, dissemination or other use of, or taking any action in reliance upon, this information by persons or entities other than the intended recipients is prohibited. If you received this in error, please contact the sender and destroy the materials contained in this message.



B-1

Practitioner Name and Address

DEA Number  
Phone  
Fax

Dear Practitioner

This medication has already been dispensed either from the contingency box or as an emergency supply as per your verbal authorization for the LTCF patient listed below. Federal law requires that a valid written and signed prescription be delivered to the pharmacy or be postmarked within 7 days. The pharmacy is also required to notify DEA if any prescriber fails to comply with this law. Please prepare a valid signed and written prescription with all of the required information listed below.

It is especially important to document the written prescription with the date of the verbal authorization for emergency dispensing and to also date the written prescription at the time of signature.

If you have any questions or concerns, please contact the pharmacy at 215-444-1212.

LTCF patient:

RX #

Unit/Rm/Bed  
DOB  
Pat ID

Date of Authorization

(or Emergency Dispensing):

07/26/2011

Medication:

OXYCODONE/APAP 6-325MG TABLET

Qty Authorized:

5 (FIVE) TABLET

Directions:

TAKE 1 TAB BY MOUTH EVERY 4 HOURS AS NEEDED FOR BACK PAIN

Valid controlled substance prescriptions must contain all of the required elements of a prescription listed below, along with your signature.

Date of Authorization for Emergency Dispensing			
Patient Full Name			
Patient Full Address		Street Address	
		City	State Zip Code
MEDICATION name strength dosage/Form			
Quantity Authorized (numeric)		Quantity Authorized (alphabetical)	
Directions for use			
Practitioner Full Name			
Practitioner Full Address		Street Address	
		City	State Zip Code
Signature of Practitioner		Substitution Permissible	Dispense As Written
Date signed		DEA Number	

The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. The disclosure of which is governed by applicable law. Any review, copying, dissemination or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you receive this in error please contact the sender and destroy the materials contained in this message.

DEA#  
PH#  
FAX#

DEAR PRACTITIONER  
This medication has already been dispensed either from the contingency box or as an emergency supply as per your verbal authorization for the LTCF patient listed below. Federal law requires that a valid written and signed prescription be delivered to the pharmacy or be postmarked within 7 days. The pharmacy is also required to notify the DEA if any practitioner fails to comply with this law. Please prepare a valid written, signed prescription with all of the required information listed below.

It is especially important to document the written prescription with the date of the verbal authorization for emergency dispensing and to also date the written prescription at the time of signature.

PATIENT: PAT ID :  
ADDRESS: RX# :  
DOB :

DATE OF AUTHORIZATION  
FOR EMERGENCY DISPENSING: 11/9/2011  
MEDICATION: OXYCODONE/APAP 5-325MG TABLET  
QTY: 5 (Five) TABLET  
DIRECTIONS: TAKE 1 TABLET ORALLY EVERY 6 HOURS  
AS NEEDED (DX: BACK PAIN) \*VERBAL\*

\*\*\* Valid controlled substance prescriptions must contain all of the required elements of a prescription listed below, along with your signature.\*\*\*

Date of Authorization for Emergency Dispensing: \_\_\_\_\_  
Patient Full Name: \_\_\_\_\_  
Patient Full Address: \_\_\_\_\_

Medication Name/Strength: \_\_\_\_\_  
Dosage Form: \_\_\_\_\_  
Quantity Prescribed: \_\_\_\_\_ (numeric)  
\_\_\_\_\_ (alpha)  
Directions for use: \_\_\_\_\_

Practitioner Name: \_\_\_\_\_  
Practitioner Full Address: \_\_\_\_\_  
Practitioner DEA Number: \_\_\_\_\_  
Practitioner Signature: \_\_\_\_\_  
Date Signed: \_\_\_\_\_

This information is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material, the disclosure of which is governed by applicable law. Any review, reproduction, dissemination or other use of, or taking any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and destroy the materials contained in this message.



Practitioner Name and Address

DEA Number  
Phone  
Fax

Dear Practitioner

This medication has already been dispensed either from the contingency box or as an emergency supply as per your verbal authorization for the LTCF patient listed below. Federal law requires that a valid written and signed prescription be delivered to the pharmacy or be postmarked within 7 days. The pharmacy is also required to notify DEA if any prescriber fails to comply with this law. Please prepare a valid signed and written prescription with all of the required information listed below.

It is especially important to document the written prescription with the date of the verbal authorization for emergency dispensing and to also date the written prescription at the time of signature.

If you have any questions or concerns, please contact the pharmacy at 215-444-1212.

LTCF patient:

RX #

Unit/Rm/Bed  
DOB  
Pat ID

Date of Authorization  
for Emergency Dispensing:

07/28/2011

Medication:

OXYCODONE/APAP 5-325MG TABLET

Qty Authorized:

5 (FIVE) TABLET

Directions:

TAKE 1 TAB BY MOUTH EVERY 4 HOURS AS NEEDED FOR BACK PAIN

Valid controlled substance prescriptions must contain all of the required elements of a prescription listed below, along with your signature.

Date of Authorization for Emergency Dispensing	07/28/2011		
Patient Full Name			
Patient Full Address	Street Address		
	City	State	Zip Code
MEDICATION name strength dosageform			
Quantity Authorized (numeric)		Quantity Authorized (alphabetical)	
Directions for use			
Practitioner Full Name			
Practitioner Full Address	Street Address		
	City	State	Zip Code
Signature of Practitioner	Substitution Permissible	Dispense As Written	
Date signed		DEA Number	

The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. The disclosure of which is governed by applicable law. Any copies, reproduction, dissemination or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you receive this in error please contact the sender and destroy the materials contained in this message.

DEA#  
PH#  
FAX#

DEAR PRACTITIONER

This medication has already been dispensed either from the contingency box or as an emergency supply as per your verbal authorization for the LTCF patient listed below. Federal law requires that a valid written and signed prescription be delivered to the pharmacy or be postmarked within 7 days. The pharmacy is also required to notify the DEA if any practitioner fails to comply with this law. Please prepare a valid written, signed prescription with all of the required information listed below.

It is especially important to document the written prescription with the date of the verbal authorization for emergency dispensing and to also date the written prescription at the time of signature.

PATIENT: PAT ID :  
ADDRESS: RX# :  
DOB :

DATE OF AUTHORIZATION

FOR EMERGENCY DISPENSING: 11/9/2011  
MEDICATION: OXYCODONE/APAP 5-325MG TABLET  
QTY: 5 (Five) TABLET  
DIRECTIONS: TAKE 1 TABLET ORALLY EVERY 6 HOURS  
AS NEEDED (DX: BACK PAIN) \*VERBAL\*

\*\*\* Valid controlled substance prescriptions must contain all of the required elements of a prescription listed below, along with your signature.\*\*\*

Date of Authorization for Emergency Dispensing: 11/9/2011

Patient Full Name: \_\_\_\_\_

Patient Full Address: \_\_\_\_\_

Medication Name/Strength: \_\_\_\_\_

Dosage Form: \_\_\_\_\_

Quantity Prescribed: \_\_\_\_\_ (numeric)

Directions for use: \_\_\_\_\_ (alpha)

Practitioner Name: \_\_\_\_\_

Practitioner Full Address: \_\_\_\_\_

Practitioner DEA Number: \_\_\_\_\_

Practitioner Signature: \_\_\_\_\_

Date Signed: \_\_\_\_\_

This information is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. The disclosure of which is governed by applicable law. Any review, reproduction, dissemination or other use of, or taking any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and destroy the materials contained in this message.